- Home
- SABS vs CLRB Comparison
SABS vs CLRB Comparison
Compare SABS & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SABS
- CLRB
- Stock Information
- Founded
- SABS 2014
- CLRB 2002
- Country
- SABS United States
- CLRB United States
- Employees
- SABS N/A
- CLRB 11
- Industry
- SABS Biotechnology: Pharmaceutical Preparations
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- SABS Health Care
- CLRB Health Care
- Exchange
- SABS Nasdaq
- CLRB Nasdaq
- Market Cap
- SABS 11.4M
- CLRB 13.4M
- IPO Year
- SABS N/A
- CLRB N/A
- Fundamental
- Price
- SABS $1.75
- CLRB $0.31
- Analyst Decision
- SABS Strong Buy
- CLRB Hold
- Analyst Count
- SABS 5
- CLRB 1
- Target Price
- SABS $11.40
- CLRB N/A
- AVG Volume (30 Days)
- SABS 25.4K
- CLRB 619.8K
- Earning Date
- SABS 05-19-2025
- CLRB 05-13-2025
- Dividend Yield
- SABS N/A
- CLRB N/A
- EPS Growth
- SABS N/A
- CLRB N/A
- EPS
- SABS N/A
- CLRB N/A
- Revenue
- SABS $1,322,410.00
- CLRB N/A
- Revenue This Year
- SABS N/A
- CLRB N/A
- Revenue Next Year
- SABS $50.00
- CLRB N/A
- P/E Ratio
- SABS N/A
- CLRB N/A
- Revenue Growth
- SABS N/A
- CLRB N/A
- 52 Week Low
- SABS $1.00
- CLRB $0.22
- 52 Week High
- SABS $5.01
- CLRB $3.51
- Technical
- Relative Strength Index (RSI)
- SABS 63.35
- CLRB 52.74
- Support Level
- SABS $1.30
- CLRB $0.23
- Resistance Level
- SABS $1.49
- CLRB $0.32
- Average True Range (ATR)
- SABS 0.14
- CLRB 0.02
- MACD
- SABS 0.06
- CLRB 0.00
- Stochastic Oscillator
- SABS 100.00
- CLRB 88.89
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.